logo mainlogo darklogo main
  • Profile
  • People
  • Portfolio
  • Press
  • Contact Us
logo main logo darklogo light
  • Profile
  • People
  • Portfolio
  • Press
  • Contact Us
Glycocalyx-targeted therapy ameliorates age-related arterial dysfunction
February 14, 2023

Glycocalyx-targeted therapy ameliorates age-related arterial dysfunction

Advanced age is accompanied by arterial dysfunction, as well as a diminished glycocalyx, which may be linked to reduced high molecular weight–hyaluronan (HMW-HA) synthesis.

Read More
Biomarkers in Children With Sepsis
January 4, 2023

Endothelial and Glycocalyx Biomarkers in Children With Sepsis After One Bolus of Unbalanced or Balanced Crystalloids

The primary outcome was endothelial glycocalyx disruption (using perfused boundary region >2 µm on sublingual video microscopy and syndecan-1 greater than 80 mg/dL) according to

Read More
Microvascular Rarefaction in Vascular Cognitive Impairment and Heart Failure
December 29, 2022

Evaluation of miCRovascular rarefaction in vascUlar Cognitive Impairment and heArt faiLure (CRUCIAL): Study protocol for an observational study

Microvascular rarefaction, the functional reduction in perfused microvessels and structural reduction of microvascular density, seems to be an important mechanism in the pathophysi

Read More
endotheliopathy-morphofunctional
December 21, 2022

Relationship of the main indicators of systemic COVID-associated endotheliopathy with the morphofunctional state and hemodynamics of the retina and chorioid in the acute period of the disease

Nonspecific angio- and retinopathy is one of the clinical manifestations of a new coronavirus infection. The frequency of occurrence of these changes in people with severe COVID-19

Read More
A Dietary Supplement Containing Fucoidan Preserves Endothelial Glycocalyx through ERK/MAPK Signaling and Protects against Damage Induced by CKD Serum
December 20, 2022

A Dietary Supplement Containing Fucoidan Preserves Endothelial Glycocalyx through ERK/MAPK Signaling and Protects against Damage Induced by CKD Serum

Damage to the endothelial glycocalyx (eGC), a protective layer lining the endothelial luminal surface, is associated with chronic kidney disease (CKD), which leads to a worsening o

Read More
Endothelial Damage and the Microcirculation in Critical Illness
December 6, 2022

Endothelial Damage and the Microcirculation in Critical Illness

Endothelial integrity maintains microcirculatory flow and tissue oxygen delivery. The endothelial glycocalyx is involved in cell signalling, coagulation and inflammation.

Read More
mediated dilation between plaque psoriasis and psoriatic arthritis
October 3, 2022

Differences in coronary flow reserve and flow-mediated dilation between plaque psoriasis and psoriatic arthritis

We aimed to investigate endothelial glycocalyx, coronary microcirculatory function and flow-mediated dilation in patients with plaque psoriasis and psoriatic arthritis.

Read More
antiretroviral therapy
October 3, 2022

Endothelial glycocalyx improvement after six months and one-year of antiretroviral therapy in treatment naive patients with human immunodeficiency virus

Chronic inflammation induced by Human Immunodeficiency Virus (HIV) plays a key role in the development of early cardiovascular (CV) disease. The impact of currently recommended fir

Read More
decresed-nitric-oxide
October 3, 2022

Endothelial dysfunction due to decreased nitric oxide bioavailability in dysglycaemic subjects and first-degree relatives of type 2 diabetic patients

We aimed to investigate oxidative stress and nitrites/nitrates concentrations at baseline and during postprandial hyperglycaemia in 40 first-degree relatives (FDR) of type 2 diabet

Read More
capillary rarefication in long COVID syndrome
August 11, 2022

Persistent capillary rarefication in long COVID syndrome

Recent studies have highlighted Coronavirus disease 2019 (COVID-19) as a multisystemic vascular disease. Up to 60% of the patients suffer from long-term sequelae and persistent sym

Read More
BioRegenx
About BioRegenx
  • Profile
  • People
  • Portfolio
  • Press
  • Contact Us
Get in touch

PO Box 21210
Chattanooga TN, 37424

(800) 398 - 9842

support@bioregenx.com

Headquarters in Chattanooga, TN
Additional Offices in Alpine, UT

Copyright © 2023 BioRegenx, Inc. All rights reserved

7407 Ziegler Rd Chattanooga, TN 37421

(800) 398 - 9842

support@bioregenx.com